Clinical Trial Search

Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants

Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…

Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants

Primary: Progression-Free Survival (PFS) — 30.6 Months

Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants

Primary: Percentages of Participants With Pathologic Complete Response — 48 percentage of participants

Primary: Number of Participants of Clinically Relevant Toxicities (CRT) — 36; 13; 42; 26 Participants

Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004

Primary: PD-1 Expression — 0; 0; 0; 0 percentage

Primary: Percentage of Patients Who Are Progression Free at 6 Months or Later. — 86 percentage of partcipants

Primary: Treatment-emergent Adverse Events Following Treatment With DS-8201a (Trastuzumab Deruxtecan) — 12; 12; 7; 6 Participants

Primary: Maximum Tolerated Dose of Ruxolitinib in Combination With Trastuzumab (Phase I) — 25 milligrams

Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants

Primary: Number of Patients With Grade 3 or Higher Toxicity Per Study Arm. — 2; 0 Participants

Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants